Home » Newsletters » BioWorld Science

BioWorld Science

Jan. 26, 2022

View Archived Issues

BUB1 biallelic mutations seen to cause microcephaly and developmental delay

STK26 and DPP4 identified as markers tied to severe COVID-19 risk

Therapeutic CAR T cells generated in the body reduce fibrosis in heart disease model in vivo

Pro-IL-12 could treat tumors with reduced toxicity compared to recombinant IL-12

Discovery of VU-6015241, a novel M4 antagonist with promising preclinical profile

Hefei Amvite Pharmaceutical patents histamine H1 receptor antagonists

Shanghai Antengene discloses new ATR kinase inhibitors

Qilu Regor Therapeutics synthesizes new MAP4K1 inhibitors

Shanghai Medicilon presents new S1PR1 modulators

Jiangsu Simcere Medical Equipment divulges new PRMT5 inhibitors

HCW-9218 potentiates antitumor efficacy by reducing TIS-driven proinflammatory phenotype

IMX-110 + anti-PD-1 extend median survival in genetic pancreatic cancer mouse model

INmune Bio collaborates with CUHK to evaluate INKmune in nasopharyngeal cancer

Siga and Bioarchitech collaborate to study Tpoxx with vaccinia-based immunotherapy platform

Tumorad significantly reduces tumor growth and prolongs survival in colorectal cancer model

MAP-tau map of interactions shows more than microtubules

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for Aug. 3, 2026.
Tuojie Biotech (Shanghai) synthesizes new SARM1 inhibitors
BioWorld Science
Tuojie Biotech (Shanghai) Co. Ltd. has prepared and tested NAD(+) hydrolase SARM1 (SAMD2; MyD88-5) inhibitors found to be potentially useful for the treatment of...
Death in Chinese gene-editing trial exposes ethical fault lines
BioWorld
The death of a 6-year-old girl after receiving an experimental brain-directed gene-editing therapy at the Xinhua Hospital in Shanghai has reopened debate over how...
Seed funding at Adjuvia to treat mitochondrial dysfunction
BioWorld Science
Adjuvia Therapeutics Inc. has closed a $8 million series seed financing round to advance its work developing therapeutics to treat mitochondrial dysfunction and...
Replimune’s RP-1 for melanoma wins over FDA adcom
BioWorld
Following two complete response letters in the past year, Replimune Group Inc.’s RP-1 (suvolimogene oderparepvec) for unresectable metastatic cutaneous melanoma...